# Aglaia BioMedical Ventures

> Aglaia BioMedical Ventures is a VC fund backing Biotechnology. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bilthoven, The Netherlands
- Total investments: 10
- Last investment: Oct 2021
- Lead investor: 30%
- Fund size: $65M
- Last fund: Sep 2014
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/aglaia-biomedical-ventures
- Website: http://www.aglaia-biomedical.com

Aglaia BioMedical Ventures is a VC fund in Bilthoven focused on Biotechnology and Therapeutics. Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

## Contacts

5 contacts available for Aglaia BioMedical Ventures. Shizune tracks 1 team members at Aglaia BioMedical Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aglaia-biomedical-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.2M–$16M |
| Series B | $20M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 70% |
| Therapeutics | 4 | 40% |
| Pharmaceutical | 4 | 40% |
| Medical | 2 | 20% |
| Health Care | 2 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 40% |
| Series B | 3 | 30% |
| Seed | 1 | 10% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 4 | 40% |
| United States | 2 | 20% |
| Switzerland | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mark Krul | Partner | 1 | https://shizune.co/investors/profile/mark-krul |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sapreme Technologies | Sapreme Technologies is a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutic. | $17.3M | Series A | Oct 07, 2021 |  |
| InteRNA Technologies | InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatmentNijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investorsparticipating in this round include the 'Innovation & Investment Fund Gelderland', managed by PPM Oost and several business angels. | $22.4M | Series B | Feb 09, 2021 |  |
| Inthera Bioscience | Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland. | $5.2M | Series A | Jun 26, 2018 |  |
| Mimetas | MIMETAS develops predictive Organ-on-a-Chip cell culture models for better, more reliable and tailored medicines. A significant gap exist between the predictive value of various in vitro and animal screening models and a patient. MIMETAS fills this gap with its OrganoPlates featuring organotypic screening models that have an improved predictabilityand can be screened at a high throughput. | $20.5M | Series B | Apr 11, 2018 |  |
| Inthera Bioscience | Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland. | $12.2M | Series A | May 31, 2017 |  |
| Cristal Therapeutics | Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies. It aims to find valuable solutions for medical needs by creating superior drug products. Both new and existing drugs can be combined with Cristal Therapeutics Polymeric Technologies, shortly abbreviated as CriPec.CriPec-based products are versatile as a crystal and allow to improve the treatment of various diseases. | $13.6M |  | Jan 19, 2017 |  |
| Macrophage Pharma | Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The company’s technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body’s natural immune system tofight cancer. | $11.8M | Series A | Jan 09, 2017 |  |
| InteRNA Technologies | InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatmentNijmegen/Utrecht (the Netherlands) – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investorsparticipating in this round include the 'Innovation & Investment Fund Gelderland', managed by PPM Oost and several business angels. | $10.5M | Series A | Dec 15, 2015 |  |
| Inthera Bioscience | Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland. | $3.7M | Seed | Dec 14, 2015 |  |
| Merus | Merus is a biotechnology company that discovers and develops new treatments for cancer patients. The company utilizes its proprietary Multiclonics Platform technology to advance its clinical pipeline of medicines. Merus conducts scientific research and clinical trials focused on developing novel treatments. | $23M | Series B | Jan 29, 2010 |  |

10 of 10 investments shown.

## Co-investors
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 3 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [Aurora Science](https://shizune.co/investors/profile/aurora-science) — VC Fund, 2 deals together
- [OostNL](https://shizune.co/investors/profile/oostnl) — VC Fund, 2 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 1 deal together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Switzerland](https://shizune.co/investors/biotechnology-investors-switzerland)
- [Biotechnology VC Funds in Switzerland](https://shizune.co/investors/biotechnology-vc-funds-switzerland)
- [Health Care Investors in Switzerland](https://shizune.co/investors/health-care-investors-switzerland)
- [Health Care VC Funds in Switzerland](https://shizune.co/investors/health-care-vc-funds-switzerland)
- [Biotech Investors in Switzerland](https://shizune.co/investors/biotech-investors-switzerland)
- [Biotech VC Funds in Switzerland](https://shizune.co/investors/biotech-vc-funds-switzerland)

## FAQ

### What does Aglaia BioMedical Ventures invest in?

Aglaia BioMedical Ventures invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Aglaia BioMedical Ventures's check size?

Aglaia BioMedical Ventures typically joins rounds of $5.2M–$16M at Series A and $20M–$23M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aglaia BioMedical Ventures participates in.

### How do I contact Aglaia BioMedical Ventures?

Public channels for Aglaia BioMedical Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aglaia BioMedical Ventures?

The team at Aglaia BioMedical Ventures includes Mark Krul (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co